Comment

  • 11 December 2018

    Future NASH reimbursement issues may echo HCV therapies

    Nonalcoholic steatohepatitis (NASH) therapies with prospective launches post-2020 will likely have reimbursement challenges mirroring those faced by hepatitis C (HCV) therapies approved five years ago, experts said.

  • 10 December 2018

    Foamix’s rosacea drug FMX103 splits views on sunburn risk

    Foamix Pharmaceuticals’ FMX103 (1.5% topical minocycline foam) has experts split over the drug’s real-world ability to protect against sunburn, despite expected FDA approval for moderate-to-severe facial papulopustular rosacea.

Go Top